Solutions

Hepatotoxicity is an essential part of any drug testing measure for many studies that are essential to test the drug’s safety. Since the largest organ gets first affected by the toxicity in the drug development, impacting several drug discoveries. We often simplify the process and allow the in vivo studies to a small number of late-stage compounds. This measure will save both time and money. Stellixir Biotech conducts assays on human primary cells; however, it becomes a task to predict the Drug-Induced Liver Injury, which can be due to several factors. Such as reactive metabolites and reactive oxygen species (ROS), the disruption of mitochondrial function and inflammatory reactions can cause damage to the liver on a cellular level and harm its protective responses as well. Therefore, we use multiple assays to assess the DILI conditions.

We have used Stellixir Biotech’s expertise to conduct two panels of assays that require a high-throughput screening panel. It will enable us to get a quick and direct hepatoxicity evaluation.

In Vitro Toxicity Panel at Stellixir Biotech

• Using HepG2, HUH7, Hep3B cell lines and human iPSC HepRG spheroid cultures
• Drug-induced phospholipidosis and steatosis
• Lysosomal trapping (lysosomotropic)
• Cholestasis
• Mitochondrial permeability transition

DILI Mechanistic Panel:

A panel of 8 assays measuring 12 end-points providing a detailed assessment of known indicators of DILI, including human hepatocyte toxicity, mitochondrial impairment, reactive metabolites formation, cholestasis, phospholipidosis, and key cellular markers of liver injury, such as cell viability, nuclear size, mitochondrial membrane potential, intracellular free calcium, and cell membrane integrity.